Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Infectious agent detection by nucleic acid (DNA or RNA) for Neisseria gonorrhoeae is a critical diagnostic procedure used to identify the presence of this bacterium, which is responsible for gonorrhea, a prevalent sexually transmitted disease (STD). Neisseria gonorrhoeae can infect various anatomical sites, including the reproductive tract, mouth, throat, eyes, and anus, primarily through direct contact during sexual activity. The infection often remains asymptomatic in women, which can lead to severe complications such as irreversible reproductive tract damage and infertility. In contrast, men typically exhibit symptoms such as burning, itching, and urethral discharge, although they are less likely to experience long-term reproductive damage. The procedure utilizes nucleic acid testing methods, which may include rapid tests that can be conducted in a physician's office using specific test kits. A specimen is collected via a swab from the cervix, male urethra, mouth, throat, or eye, depending on the site of suspected infection. The methodology for detecting N. gonorrhoeae varies based on the test kit employed, with some kits utilizing a nucleic acid hybridization technique. This involves the use of a single-stranded chemiluminescent DNA probe that is complementary to the ribosomal RNA of the organism. The process includes lysing cells to release nucleic acids, followed by the formation of stable DNA:RNA hybrids, which are then detected using a luminometer. This procedure is essential for timely diagnosis and treatment of gonorrhea, thereby preventing potential complications associated with untreated infections.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure for detecting Neisseria gonorrhoeae using nucleic acid techniques is indicated for the following conditions:
The procedure for detecting Neisseria gonorrhoeae involves several key steps, which are detailed below:
After the procedure, the results of the nucleic acid test for Neisseria gonorrhoeae are typically available within a short timeframe, especially if a rapid test is utilized. Patients may be advised to follow up with their healthcare provider to discuss the results and any necessary treatment options. If the test is positive, appropriate antibiotic therapy will be initiated to treat the infection. Additionally, patients may be counseled on safe sexual practices to prevent reinfection and the spread of the disease. It is also important for sexual partners to be informed and tested to ensure comprehensive management of the infection.
| Short Descr | N.GONORRHOEAE DNA DIR PROB | Medium Descr | IADNA NEISSERIA GONORRHOEAE DIRECT PROBE TQ | Long Descr | Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 206 - Microscopic examination (bacterial smear, culture, toxicology) |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Short description changed. |
| 1998-01-01 | Added | First appearance in code book in 1998. |
Get instant expert-level medical coding assistance.